Morgan Stanley analyst Alexandra Steiger maintains Nike (NYSE:NKE) with a Overweight and raises the price target from $138 to $140.
Novo Nordisk Faces Scrutiny Over High Prices of Ozempic And Wegovy, Blames US Health System
Novo Nordisk retains around 60% of the list price for its diabetes and obesity medications, Ozempic and Wegovy, after rebates and fees.